Pharmarest's Global Positioning Reinforced at AMWC Korea 2026

Pharmarest, led by CEO Son Ji-hoon, announced on the 23rd its successful participation in the inaugural Aesthetic & Anti-aging Medicine World Congress (AMWC) Korea 2026 held at the Grand InterContinental Seoul Parnas. During the event, Pharmarest showcased its total aesthetic solution focused on Rejuran, illustrating its commitment to advancing the field of regenerative medicine.

The AMWC serves as a premier platform for sharing cutting-edge clinical experiences and treatment trends in aesthetic medicine and anti-aging. The high attendance of global medical professionals and industry stakeholders at this year's first AMWC Korea underscores a growing interest in the Korean medical aesthetics market. This interest is pivotal for global distributors and retailers looking to engage with innovative products.

At the event, Pharmarest presented its skin booster Rejuran, derived from salmon DNA and based on DOT PN (Polynucleotide) technology, as the cornerstone of its aesthetic portfolio. Alongside Rejuran, the company featured HA (Hyaluronic Acid) filler Cleveal, botulinum toxin type A product Rientox, and PN-based joint injection product Conjuran, showcasing a comprehensive range that bridges both aesthetic and therapeutic realms.

Notably, Pharmarest received the AMWC award for 'Best Injectable for Skin Revitalization,' further cementing its status as a leading entity in the global medical aesthetics landscape. This recognition speaks volumes about the established regenerative medicine capabilities and the well-aging strategies attributed to Rejuran, reflecting a robust competitive differentiator in the market.

Pharmarest also introduced various programs aimed at enhancing the Rejuran brand experience, including the Rejumate injector and the Rejuran Professional Care Program for medical institutions. These initiatives emphasize a total aesthetic solution that considers both the clinical environment for practitioners and the patient care experience, signaling innovative pathways for customer retention.

During the academic sessions, the clinical applications of Rejuran were extensively discussed. Dr. Suneel Chilukuri, a leading dermatologist from the United States, shared evidence-based insights on the mechanisms of action of PN, while Dr. Park Hyun-jun of Cheongdam Maylin Medical Clinic presented strategies for improving concerns such as pores, pigmentation, and erythema when combined with Energy-Based Devices (EBD).

Pharmarest officials stated that AMWC Korea, being the first global academic event hosted in South Korea, provided a significant opportunity to directly present their total aesthetic solutions to international medical professionals. With the recognition from the AMWC Awards solidifying Rejuran’s competitiveness on a global scale, Pharmarest aims to continue enhancing its research and academic exchanges to further strengthen its influence in the global medical aesthetics market.